Cediranib - Wikipedia
Cediranib (AZD-2171; tentative trade name Recentin) is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases. [1] [2] [3] The drug is being developed by AstraZeneca as a possible anti-cancer chemotherapeutic agent for oral administration.
Cediranib: Uses, Interactions, Mechanism of Action - DrugBank …
2007年10月18日 · Cediranib is a once-daily, orally available, highly potent and selective VEGF signalling inhibitor that inhibits all three VEGF receptors. The preclinical profile of Cediranib indicates that it has the potential to be the 'best in class' VEGF signalling inhibitor.
Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor ...
Cediranib is an oral tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptor (VEGFR) -1, VEGFR-2, VEGFR-3, and c-kit. We conducted a phase II study of cediranib for recurrent EOC or peritoneal or fallopian tube cancer; cediranib was administered as a daily oral dose, and the original dose was 45 mg daily.
Cediranib | C25H27FN4O3 | CID 9933475 - PubChem
The novel indole -ether quinazoline Cediranib is a highly potent (IC 50 < 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro. It is being developed clinically as a once-daily oral therapy for the treatment of cancer.
Cediranib - an overview | ScienceDirect Topics
Cediranib is an oral medication that inhibits vascular endothelial growth factor-A signaling, used to stabilize the progression of solid malignancies by blocking tumor-induced angiogenesis. AI generated definition based on: xPharm: The Comprehensive Pharmacology Reference , 2010
Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor ...
2009年10月13日 · Cediranib is an oral tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptor (VEGFR) -1, VEGFR-2, VEGFR-3, and c-kit. We conducted a phase II study of cediranib for recurrent EOC or peritoneal or fallopian tube cancer; cediranib was administered as a daily oral dose, and the original dose was 45 mg daily.
Clinical Pharmacokinetics and Pharmacodynamics of Cediranib
Cediranib potently and selectively inhibits all three vascular endothelial growth factor receptors (VEGFR-1, -2 and -3), and clinical studies have shown that it is effective in patients with ovarian cancer at a dose of 20 mg/day.
Cediranib – Profile of a novel anti-angiogenic agent in patients …
Among a number of novel targeted therapeutics evaluated in preclinical studies and recent clinical trials, the oral pan-VEGF receptor tyrosine kinase inhibitor cediranib has emerged as a promising agent with potent anti-angiogenic properties.
Cediranib, a pan-inhibitor of vascular endothelial growth factor ...
2021年12月15日 · Key findings: Cediranib reduced GB cell proliferation, induced apoptotic cell death and inhibited the aggressive abilities of GB cells. Cediranib synergistically increased the anti-proliferative and apoptotic effects of radiotherapy and bevacizumab and augmented the sensitivity of GB cells to temozolomide chemotherapy.
Update on Phase III GY004 trial for cediranib added to Lynparza in ...
2020年3月12日 · Cediranib is an oral vascular endothelial growth factor (VEGF) receptor inhibitor that has demonstrated efficacy as a monotherapy and in combination in various cancers. Cediranib has shown anti-tumour activity in many cancers, including ovarian, breast, colorectal, renal, lung, sarcoma and glioblastoma.
跳至内容